REGULATORY INTELLIGENCE·Warning Letter
Biogen's Tecfidera Recall: Critical cGMP Deviations Impact US Pharmaceutical Supply Chain
Biogen Inc. initiated a Class III recall of 3,922 bottles of Tecfidera (dimethyl fumarate) due to cGMP deviations, specifically distributing a lot rejected during in-process control. This event, now terminated, highlights critical quality control vulnerabilities for pharmaceutical procurement and supply chain leaders, emphasizing the imperative for stringent supplier oversight and robust internal quality assurance protocols.
90-Day Activity